Pioneering the development
of engineered IgM antibodies

antibody-solo

Agonistic Death Receptor 5 (DR5) IgM antibody IGM-8444 induces tumor cell apoptosis in vitro and in vivo and has a favorable in vitro safety profile

May 15, 2020
Read More...

A bispecific IgM antibody format for enhanced T cell dependent killing with minimal cytokine release

May 15, 2020
Read More...

IGM-8444 as a potent agonistic Death Receptor 5 (DR5) IgM antibody: Induction of tumor cytotoxicity, combination with chemotherapy and in vitro safety profile.

May 13, 2020
Read More...

Lymphoma cell-killing activity and cytokine release by CD20-directed bispecific IgM antibody-based T-cell engager (IGM-2323)

May 13, 2020
Read More...

IGM Biosciences to Present at the 2020 RBC Capital Markets Global Healthcare Conference

May 12, 2020

MOUNTAIN VIEW, Calif., May 12, 2020 – IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology…

Read More...

IGM Biosciences Announces First Quarter 2020 Financial Results and Provides Corporate Update

May 7, 2020

– Initial data from Phase 1 trial of IGM-2323 in relapsed/refractory non-Hodgkin’s lymphoma expected in…

Read More...